Who is sponsoring NCT04986878?

NCT04986878 is sponsored by Aswan University Hospital.

What drugs are being tested in NCT04986878?

Interventions in NCT04986878: single-shot adductor canal block.

What condition does NCT04986878 study?

NCT04986878 studies Rheumatism Knee.

Is NCT04986878 still recruiting?

NCT04986878 is currently completed. Last updated 4 August 2021.

Last reviewed 2021-08-04 · How we verify

NCT04986878

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Single Shot Versus Continuous Adductor Canal Block in Patients Undergoing Total Knee Arthroplasty

Completed NA Last updated 4 August 2021

What this trial tests

NA trial testing single-shot adductor canal block in Rheumatism Knee in 60 participants. Completed in 30 June 2018.

Timeline

15 March 2017

Primary endpoint
31 March 2018

30 June 2018

Quick facts

Lead sponsor	Aswan University Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	15 March 2017
Primary completion	31 March 2018
Estimated completion	30 June 2018
Sites	2 locations across Egypt

Drugs / interventions tested

single-shot adductor canal block

Conditions studied

Rheumatism Knee — all drugs for Rheumatism Knee →

Sponsor

Aswan University Hospital

Who can join

Adults 18 to 70, any sex, with Rheumatism Knee. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Adductor canal block (ACB) has emerged as an option for postoperative regional analgesia in patients undergoing total knee arthroplasty (TKA).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Aswan University Hospital trials

Trials by the same sponsor.

NCT06491394 — Lactoferrin Effect on Kidney and Heart of Rhabdomyolysis Rats · Phase 4 · completed
NCT06211088 — Famotidine Versus Placebo in Emergency Pediatric Surgery As a Risk to Postoperative Nausea and Vomiting · NA · completed
NCT06583590 — Evaluation of Efficacy of Botulinum Toxin A Plus Oral Tadalafil 5 mg in Diabetic Men With Erectile Dysfunction · Phase 2, PHASE3 · recruiting
NCT06537323 — Femoral Nerve Block, Periarticular Nerve Group (PENG) Block, and Preoperative IV Fentanyl · NA · recruiting
NCT06535256 — Compare Intraperitoneal Instillation of Bupivacaine+dexmedetomidine Versus Bupivacaine+dexamethasone on Postoperative Pa · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04986878 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aswan University Hospital
Last refreshed: 4 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04986878.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing